Millipore Sigma Vibrant Logo

420106 JAK3 Inhibitor III

420106
  
Recuperando precio...
No pudo obtenerse el precio
La cantidad mínima tiene que ser múltiplo de
Maximum Quantity is
Al finalizar el pedido Más información
Ahorró ()
 
Solicitar precio
Disponibilidad a confirmar
Disponibilidad a confirmar
Ingrese cantidad 
Suspendido
Cantidades limitadas disponibles
Debe confirmarse disponibilidad
    El resto: se avisará
      El resto: se avisará
      Se avisará
      Póngase en contacto con el Servicio de Atención al Cliente
      Contact Customer Service

       

      Póngase en contacto con el Servicio de Atención al Cliente

      Descripción

      Replacement Information
      Description
      Overview

      This product has been discontinued.

      Please refer to our complete listing of JAK3 inhibitors for possible alternatives. Please read all alternative product documentation carefully and contact technical service if you need additional information.





      A potent cell-permeable and specific inhibitor of JAK3 (IC50 = 11 µM). Inhibits JAK3 in immune complex kinase assays in a dose-dependent fashion and reduces the invasiveness of EGFR positive human cancer cells in a dose-dependent manner.
      Catalogue Number420106
      Brand Family Calbiochem®
      Synonyms4-(3ʹ,5ʹ-Dibromo-4-hydroxyphenyl)amino-6,7-dimethoxyquinazoline, WHI-P97
      References
      ReferencesGhosh, S., et al. 1999. Anticancer Res. 14, 403. Sudbeck, E.A., et al. 1999 Clin. Cancer Res. 5, 1569.
      Product Information
      CAS number211555-05-4
      FormPale yellow solid
      Hill FormulaC₁₆H₁₃Br₂N₃O₃
      Chemical formulaC₁₆H₁₃Br₂N₃O₃
      Structure formula ImageStructure formula Image
      Applications
      Biological Information
      Primary TargetJAK-3
      Primary Target IC<sub>50</sub>11 µM
      Purity≥92% by HPLC
      Physicochemical Information
      Cell permeableY
      Dimensions
      Materials Information
      Toxicological Information
      Safety Information according to GHS
      Safety Information
      Product Usage Statements
      Storage and Shipping Information
      Ship Code Ambient Temperature Only
      Toxicity Standard Handling
      Storage +2°C to +8°C
      Protect from Light Protect from light
      Do not freeze Ok to freeze
      Special InstructionsFollowing reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 3 months at -20°C.
      Packaging Information
      Packaged under inert gas Packaged under inert gas
      Transport Information
      Supplemental Information
      Specifications
      Global Trade Item Number
      Número de referencia GTIN
      420106 0

      Documentation

      JAK3 Inhibitor III Certificados de análisis

      CargoNúmero de lote
      420106

      Referencias bibliográficas

      Visión general referencias
      Ghosh, S., et al. 1999. Anticancer Res. 14, 403. Sudbeck, E.A., et al. 1999 Clin. Cancer Res. 5, 1569.
      Ficha técnica

      Note that this data sheet is not lot-specific and is representative of the current specifications for this product. Please consult the vial label and the certificate of analysis for information on specific lots. Also note that shipping conditions may differ from storage conditions.

      Revision17-September-2007 JSW
      Synonyms4-(3ʹ,5ʹ-Dibromo-4-hydroxyphenyl)amino-6,7-dimethoxyquinazoline, WHI-P97
      DescriptionA potent and specific inhibitor of JAK3 (IC50 = 11 µM). Inhibits JAK3 in immune complex kinase assays in a dose-dependent fashion.
      FormPale yellow solid
      Intert gas (Yes/No) Packaged under inert gas
      CAS number211555-05-4
      Chemical formulaC₁₆H₁₃Br₂N₃O₃
      Structure formulaStructure formula
      Purity≥92% by HPLC
      SolubilityDMSO (5 mg/ml)
      Storage Protect from light
      +2°C to +8°C
      Do Not Freeze Ok to freeze
      Special InstructionsFollowing reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 3 months at -20°C.
      Toxicity Standard Handling
      ReferencesGhosh, S., et al. 1999. Anticancer Res. 14, 403. Sudbeck, E.A., et al. 1999 Clin. Cancer Res. 5, 1569.